AtriCure, Inc. ATRC

What this company does

The company develops surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. Its cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiac, thoracic or amputation surgical procedures. The company sells its products to medical centers through its direct sales force in the United States, Germany, France, the United Kingdom, the Benelux region, Australia and Canada, and through distributors that in turn sell to medical centers in other international markets. As of December 31, 2025, the company had approximately 1,350 employees. The company assembles, inspects, tests and packages the majority of its products at its facilities in Ohio, and its products are sterilized by third parties.

Written from the business description in AtriCure, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 19 February 2026. Every sentence was checked against that document before publication.